DT Cloud Acquisition Corporation Unit
DYCQU
NASDAQ Global Market12.51
USD
- -
- -
CIK
0001944212
ISIN
KYG285241090
Return %
Stock
S&P500
1Y
17.46
26.53
3Y
23.62
76.60
5Y
23.62
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Guojian Chen
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 30 Orange Street London United Kingdom
- IPO Date
- Feb 21, 2024
- CIK
- 0001944212
- Similar Companies
- Business
- DT Cloud Acquisition Corporation Unit (DYCQU) represents redeemable units of DT Cloud Acquisition Corporation, a blank check company incorporated in the Cayman Islands in 2022 and headquartered at 30 Orange Street, London, WC2H 7HF, United Kingdom; the corporation functions as a subsidiary of DT Cloud Capital Corp and conducts no significant operations beyond pursuing a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more targets, with a focus on industries complementing management expertise in technology and digital transformation sectors; units comprise one ordinary share and one right, trading on Nasdaq alongside ordinary shares (DYCQ) and rights (DYCQR). The company generates non-operating income from interest and dividends on trust account investments held in U.S. Treasuries via money market funds, while public shareholders retain redemption rights for pro rata trust proceeds upon business combination approval or liquidation; it targets no specific geography but evaluates opportunities globally, maintaining zero employees and broad discretion in deal selection provided the target meets Nasdaq minimum fair market value thresholds. In October 2024, DT Cloud entered a definitive $250 million all-stock business combination agreement with Maius Pharmaceutical Co., Ltd., a Cayman Islands biopharmaceutical R&D firm focused on anticancer drugs, autoimmune medications, and anti-infectives, involving SPAC and acquisition mergers to form Maius Pharmaceutical Group Co., Ltd. as the listed Pubco; the deal, approved by both boards and initially slated for H1 2025 completion, faced delays amid heavy shareholder redemptions reducing trust assets from $72.3 million at December 31, 2024, to $1.6 million by September 30, 2025, alongside a Q3 2025 net loss of $242,147 and shareholders' deficit of $3.3 million; to sustain pursuit, the company secured multiple extraordinary general meeting approvals for extensions—up to May 23, 2026 (March 2025), August 23, 2026 (April 2025), and February 23, 2027 (August 2025, via 24 monthly increments)—with sponsor deposits totaling $270,000 from February to September 2025, a reduced extension fee to $15,000 monthly (May 2025), fee waiver from August 2025 (Extension Fee Waiver), non-redemption agreements, a January 2025 subscription agreement for Pubco shares, and a September 29, 2025 subscription with investors; as of late 2025, Nasdaq notified of trading suspension risk for listing noncompliance, raising going concern doubts absent combination closure.